PP2A catalytic subunit silence by microRNA-429 activates AMPK and protects osteoblastic cells from dexamethasone

Area of Science:

• Molecular Biology
• Cell Biology
• Biochemistry

Background:

• Dexamethasone (Dex) induces osteoblast death, posing a challenge in bone health.
• AMP-activated protein kinase (AMPK) activation shows potential for protecting osteoblasts.
• Targeting protein phosphatase 2A (PP2A) is a strategy to modulate AMPK activity.

Purpose of the Study:

• To investigate the role of microRNA-429 (miR-429) in activating AMPK.
• To determine if miR-429 can protect osteoblasts from dexamethasone-induced damage.
• To elucidate the mechanism of miR-429-mediated osteoblast protection.

Main Methods:

• Utilized human osteoblastic cell lines (OB-6 and hFOB1.19).
• Employed miRNA-mediated gene silencing to target PP2A catalytic subunit (PP2A-c).
• Assessed AMPK activation (p-AMPKα1 Thr172), cell viability, apoptosis, and NADPH levels.
• Used shRNA and mutation to silence or inactivate AMPKα1 for mechanistic studies.

Main Results:

• miR-429 expression successfully downregulated PP2A-c and activated AMPK in osteoblasts.
• miR-429 significantly alleviated dexamethasone-induced osteoblastic cell death and apoptosis.
• The protective effects of miR-429 were dependent on AMPKα1 activation.
• miR-429 increased NADPH levels, inhibiting oxidative stress, an effect also dependent on AMPKα1.

Conclusions:

• miR-429 activates AMPK by downregulating PP2A-c in osteoblasts.
• miR-429-mediated AMPK activation protects osteoblasts from dexamethasone-induced apoptosis and oxidative stress.
• This pathway represents a novel therapeutic strategy for bone protection.